Aktieanalys

Initiator Pharma Q2 2023: Development progress - Redeye

Redeye Publicerad: 25 Aug 2023 09:29

Redeye provides a research update following the Q2 report published by Initiator Pharma earlier today. Overall, the report did not contain any significant surprises and was in line with our expectations. However, we are encouraged by the progress made in clinical development by the company during the quarter. We reiterate our fair value range with a base case valuation of SEK16 as we look forward to the crucial phase IIb data readout from pudafensine expected later this year.

Länk till analysen i sin helhet: https://www.redeye.se/research/938995/initiator-pharma-q2-2023-development-progress?utm_source=finwire&utm_medium=RSS

Nyheter om Initiator Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!